删除或更新信息,请邮件至freekaoyan#163.com(#换成@)

P-糖蛋白抑制剂维拉帕米对龙血素A、B、C在大鼠体内药物动力学影响

本站小编 Free考研考试/2021-12-21

本文二维码信息
二维码(扫一下试试看!)
P-糖蛋白抑制剂维拉帕米对龙血素A、B、C在大鼠体内药物动力学影响
Effect of P-Glycoprotein Inhibitor Verapamil on Pharmacokinetics of Loureirin A B C in Rats
投稿时间:2018-07-08
DOI:10.15918/j.tbit1001-0645.2018.289
中文关键词:P糖蛋白龙血竭药物动力学维拉帕米
English Keywords:P-glycoproteinDragon's Bloodpharmacokineticverapamil
基金项目:国家自然科学基金资助项目(81573693);"1226"重大项目(AWS16J018)
作者单位E-mail
李玉娟北京理工大学 生命学院, 北京 100081lylyjlzh2006@163.com
康丽婷北京理工大学 生命学院, 北京 100081
郭晶晶北京理工大学 生命学院, 北京 100081
王识博北京理工大学 生命学院, 北京 100081
李勇枝中国航天员科研训练中心, 北京 100094
王佳平中国航天员科研训练中心, 北京 100094
高建义中国航天员科研训练中心, 北京 100094
摘要点击次数:1126
全文下载次数:340
中文摘要:
研究灌胃给予大鼠龙血竭后,P糖蛋白抑制剂维拉帕米对其有效成分龙血素A、B、C在大鼠血浆中的药物动力学影响.将SD大鼠随机分为对照组和抑制剂组并单次给药,对照组灌胃给予大鼠5 g/kg龙血竭,抑制剂组联合给予大鼠维拉帕米(1 mg/kg)和龙血竭(5 g/kg).收集两组相同系列时间的血浆样本,采用HPLC-MS/MS的方法对龙血素A、B、C在大鼠血浆中的浓度测进行检测,求算两组血浆样本药物动力学参数.与对照组相比,抑制剂组大鼠龙血素A、B、C的血药浓度-时间曲线下面积分别增加109.4%,78.5%,22.8%,血药峰浓度分别增加69.6%,115.0%,42.1%,龙血素A、B的达峰时间均延长、龙血素C的达峰时间无变化,三者的生物半衰期(T0.5)均变小,说明P糖蛋白抑制剂能够引起龙血素A、B、C在大鼠体内的血浆药物动力学参数变化,龙血素A、B、C均有可能为P糖蛋白的潜在底物.
English Summary:
To study how P-glycoprotein inhibitor verapamil affect pharmacokinetics of the active constituents Loureirin A, B and C in rat plasma after oral administration of Dragon's Blood,SD rats were randomly put into different group:control group and inhibitor group. A single dose of 5 g/kg of Dragon's Blood was orally administered to rats in control group, and rats in the inhibitor group were given verapamil (1 mg/kg) and Dragon' Blood (5 g/kg). Plasma samples were collected from the two groups in the same series of time. A HPLC-MS/MS method was used to determine the content of Loureirin A, B and C in rat plasma, and the plasma samples pharmacokinetic parameters were calculated. Comparing the area under curve (AUC0-t) of the rats in the inhibitor group with the control group, it increased by 109.4%,78.5%, 22.8%. And the peak concentration(Cmax) of Loureirin A, B and C increased by 69.6%, 115.0%, and 42.1%. The time of Loureirin A and B reaching peak concentration (tmax) was prolonged, while the tmax of Loureirin C was unchanged. All three biological half-life (t0.5) decreased. It indicates that P-glycoprotein inhibitor can significantly change the plasma pharmacokinetic parameters of Loureirin A, B and C in rats. Loureirin A, B and C may be potential substrates of P-glycoprotein. This article provides basic data for the subsequent in-depth study of the relationship between P-glycoprotein and transportation of Dragon's Blood in the intestinal tract of rats.
查看全文查看/发表评论下载PDF阅读器
相关话题/北京 北京理工大学 生命 中国航天员科研训练中心 药物